ach year, influenza and its complications are responsible for hundreds of thousands of excess hospitalizations, tens of thousands of excess deaths, and billions of dollars in health care costs (1, 2) . Elderly persons and persons with certain underlying medical conditions experience more than 80% of the serious complications of influenza, such as hospitalization and death (3, 4) . Among elderly persons, those with chronic lung disease are an especially high-risk group: Their hospitalization rates for pneumonia are 2 to 7 times those of their counterparts without underlying pulmonary conditions (5) (6) (7) . Despite long-standing recommendations for annual immunization (4) , approximately 35% of elderly persons are not vaccinated (8) . The highest-risk elderly persons, such as those with chronic lung disease, also have inadequate vaccination rates (9) .
Persistent uncertainties about the risks of influenza and the benefits of influenza vaccination may contribute to the underuse of influenza vaccine in very high-risk populations, such as elderly persons with chronic lung disease. Some studies, for example, have suggested that vaccine immunogenicity may be impaired in elderly and chronically ill populations (10, 11) . Little has been published about the clinical impact of influenza or the observed effectiveness of vaccination in persons with specific underlying medical conditions.
Of persons 65 years of age or older, 12% have chronic lung disease (9) . We conducted this cohort study to define the effects of influenza and the benefits of influenza vaccination in this very-highrisk group of chronically ill elderly persons.
Methods

Setting
Group Health, a staff-model health maintenance organization, is one of several health care plans affiliated with HealthPartners, which is a vertically integrated health care organization. Group Health has 21 clinics, 350 salaried physicians, and more than 250 000 members in the Minneapolis-St. Paul area. In 1989, it adopted a modified version of the Minneapolis Veterans Affairs Flu Shot Program and piloted it in 2 clinics (12) . The influenza vaccination program was expanded to include all of the Group Health staff clinics in 1990 and has been maintained since then. This successful program has resulted in influenza vaccination rates of 60% or more for elderly members and has been associated with improved health and decreased medical care costs for these persons (13) . Components of the program include standing orders for nurses, walk-in vaccination clinics that complement other clinic-based vaccination efforts, and reminder mailings to high-risk patients.
Cohort
All Group Health members who 1) were at least 65 years of age on 1 October 1993, 2) had received a diagnosis of chronic lung disease (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM], codes 491-496 and 500 -518) during the previous 12 months, and 3) were alive on the first day of the outcome period were included in the cohort.
Data Collection and Study Outcomes
This study is one of several projects that will assess the impact of vaccine-preventable diseases and the benefits of vaccination in this cohort of elderly persons with chronic lung disease. We previously reported the results of serial, single-season cohort studies conducted among all elderly members of Group Health (13, 14) . All of the study data were obtained from the administrative databases of Group Health. Information on the baseline demographic and health characteristics of persons in the cohort was collected for the period from 1 October 1992 through 30 September 1993 and included age, sex, number of physician visits, previous hospitalizations for pneumonia and influenza (ICD-9-CM codes 480 -487), and other high-risk diagnoses ( The primary study outcomes were the number of hospitalizations for pneumonia and influenza (ICD-9-CM codes 480 -487), the number of hospitalizations for all acute and chronic respiratory conditions (ICD-9-CM codes 460, 462, 465, 466, 480 -487, 490 -496, and 500 -518), and deaths from all causes during the three influenza seasons studied. Secondary outcomes were outpatient visits for pneumonia and influenza and outpatient visits for all acute and chronic respiratory conditions during the influenza seasons. To test the adequacy of the multivariate models, we assessed the rates of two control outcomes: 1) all noncardiopulmonary hospitalizations during the influenza seasons and 2) hospitalizations for pneumonia and influenza during the interim periods. We hypothesized that the rates of both control outcomes would be similar in the two study groups.
Outcome Periods
Outcomes were assessed from 15 November 1993 through 31 March 1996. The three influenza seasons included in the study were the main periods of interest. The dates for the influenza seasons were selected to span periods of continuous influenza activity in Minnesota and were chosen on the basis of Minnesota Department of Health influenza surveillance information (15) (16) (17) . The inclusive dates of the influenza seasons were similar for each of the study years. To facilitate data analysis, we therefore selected the same time period-15 November through 31 March-to define each influenza season for 1993-1994, 1994 -1995, and 1995-1996 . The two interim periods extended from 1 April through 14 November in 1994 and 1995.
Statistical Analysis
Baseline demographic and health characteristics in vaccinated and unvaccinated persons were compared by using Student t-tests and chi-square tests. We used generalized estimating equations to fit multivariate models so that we could compare risks for the study outcomes over the three influenza seasons or the two interim periods in vaccinated and unvaccinated persons while controlling for covariates and potential confounders (SAS, version 6.12, SAS Institute, Inc., Cary, North Carolina). The numbers of hospitalizations in the two groups were compared by using Poisson regression with repeated measures. To accommodate the assumption of a Poisson distribution, the number of hospitalizations for each person in each period was truncated at 4 (this affected Ͻ0.1% of persons for pneumonia hospitalizations, Ͻ0.1% of persons for all noncardiopulmonary hospitalizations, and Ͻ0.5% of participants for hospitalizations for all respiratory conditions). The risks for death in the two groups during the influenza seasons were compared by using logistic regression with repeated measures. For the numbers of outpatient visits, we used Poisson regression with repeated measures. To accommodate the assumption of a Poisson distribution, we confined the analysis to persons who had at least one visit and we truncated the numbers of visits for each person to 8 within each study period (this affected Ͻ0.5% of persons for outpatient visits for pneumonia and influenza and Ͻ10% of persons for outpatient visits for all respiratory conditions). To test whether the proportion of persons in the two groups who had at least one outpatient visit differed, we used logistic regression with repeated measures.
In all of these models, vaccination status was included as a time-varying covariate. Age, sex, and influenza and pneumococcal vaccination status were included in all final models. Age was dichotomized (Ͻ80 years or Ն80 years), given the skewness of the underlying distribution. All other variables listed in Table 1 were considered for inclusion in the final models because they 1) had previously been reported to be associated with increased risk for at least one of the primary study outcomes, 2) were thought to be clinically relevant, or 3) were variables for which persons studied differed significantly at baseline. Variables were selected after the use of stepwise procedures if they were associated with the outcome with a P value less than 0.2 in the full model, which included all possible variables, and if they also had a P value less than 0.1 in the final, reduced model. We also tested for evidence of interaction between influenza vaccinations and pneumococcal vaccinations. All models were adjusted for the numbers of months of follow-up available for each person in the study. A variable for year was also included in the models. Final models were reviewed to confirm the clinical appropriateness of the variable set. To ensure that the reduced models represented sufficient confounder and covariate groups, we also compared the estimate of vaccination effect seen in the full models with that seen in the reduced models, verifying that no meaningful differences in effect estimates existed between the two models.
For selected outcomes, we estimated the percentage reduction (prevented fraction) associated with vaccination. This was calculated by subtracting the risk ratio from 1 (18) . In estimating the percentage reduction in deaths associated with vaccination, we used the odds ratio as an estimate of relative risk because the outcome events were uncommon (19) .
Results
The cohort comprised 1898 persons. Influenza vaccination rates were 72%, 74%, and 75% for the 1993-1994, 1994 -1995, and 1995-1996 seasons, respectively. Among persons who had been vaccinated before the third influenza season, 76% had received immunizations for the two previous seasons and 21% had received one immunization over the two previous seasons. At baseline, persons who were vaccinated before the first influenza season were younger; more likely to be male; more likely to have received a pneumococcal vaccination; and less likely to have a diagnosis of heart disease, cancer, or dementia or stroke. They also had a higher rate of outpatient visits during the previous year ( Table 1) .
For each of the influenza seasons, significant influenza A/H3N2 activity was seen. There was also significant influenza B activity during the 1994 -1995 season and significant influenza A/H1N1 activity during the 1995-1996 season. A good to excellent match was found between vaccine and circulating virus strains for each season (Cox N. Personal communication).
A total of 112 hospitalizations for pneumonia and influenza, 566 hospitalizations for all respiratory conditions, 1113 outpatient visits for pneumonia and influenza, 9517 visits for all respiratory conditions, and 149 deaths occurred during the three influenza seasons studied. A total of 259 persons were disenrolled from the health plan at some time during the outcome period.
The observed annualized incidence rates of hospitalizations for pneumonia and influenza in each study period for vaccinated and unvaccinated persons are shown in the top panel of the Figure; the adjusted risk ratios for hospitalization for unvaccinated persons compared with vaccinated persons by study period are shown in the bottom panel of the Figure. Substantial seasonal differences were seen in the rates of hospitalization for pneumonia for unvaccinated participants, whereas this seasonal variability markedly diminished among vaccinated persons. For unvaccinated persons, the overall annualized Over the three influenza seasons, influenza vaccination was associated with a 52% reduction in the numbers of hospitalizations for pneumonia and influenza (adjusted risk ratio [RR], 0.48; P ϭ 0.008) and with a 70% reduction in risk for death (adjusted odds ratio [OR], 0.30; P Ͻ 0.001) ( Table 2 ). The number of hospitalizations for all respiratory conditions did not differ significantly between the two groups (RR, 0.76; P ϭ 0.13). For outpatient visits, influenza vaccination was not associated with a lower risk for having at least one visit for either pneumonia (OR, 0.95; P Ͼ 0.2) or all respiratory conditions (OR, 0.95; P Ͼ 0.2) during the influenza seasons ( Table 2) . However, among persons who had at least one visit, the numbers of outpatient visits were lower for both pneumonia and influenza (RR, 0.64; P ϭ 0.002) and for all respiratory conditions (RR, 0.89; P ϭ 0.002). The rates of hospitalization for the two control outcomes were similar in the two study groups (for hospitalizations for pneumonia and influenza during the interim periods: RR, 0.93 [CI, 0.52 to 1.65]; P Ͼ 0.2; for hospitalizations for noncardiopulmonary conditions during the influenza seasons: RR, 0.96 [CI, 0.70 to 1.31]; P Ͼ 0.2). However, given the wide CIs, we were unable to exclude a clinically relevant difference.
Discussion
Elderly persons with chronic lung disease have an especially high risk for complications from influenza. In this study, we demonstrate the substantial health benefits associated with influenza vaccination in this population. Over the three consecutive influenza seasons studied, immunization was associated with a 52% reduction in hospitalizations for all episodes of pneumonia and influenza and a 70% reduction in deaths from all causes. Vaccination was also associated with fewer outpatient visits for pneumonia and for all respiratory conditions. Few previous studies have assessed the benefits of influenza vaccination in adults with chronic lung disease. One small cohort study of vaccinated and unvaccinated patients attending an ambulatory clinic (20) showed that among 66 patients with underlying pulmonary disease, vaccination was associated with a 64% reduction in febrile respiratory illness and a 77% reduction in all respiratory illnesses during an influenza A season. Another study of 195 patients who were hospitalized with exacerbations of chronic airflow obstruction during an influenza season (21) showed that 20% of unvaccinated persons and only 1.4% of vaccinated persons had evidence of influenza A infection. Our study extends previous observations by showing, in a large cohort and over consecutive seasons, that vaccination of elderly persons with chronic lung disease is associated with significantly fewer outpatient visits, hospitalizations, and deaths due to complications of influenza.
As has been noted elsewhere for elderly persons with chronic pulmonary disease (5-7), our study participants were at especially high risk for hospitalization due to pneumonia and influenza during the influenza seasons: They had hospitalization rates more than four times higher than those of their Group Health counterparts who did not have underlying lung disease (Nichol KL. Personal communication). Nevertheless, the clinical effectiveness of vaccination in our study was similar to that seen in previous studies of unselected elderly persons. Influenza vaccination in a placebo-controlled trial of low-risk older adults reduced rates of clinical and serologic influenza by 58% (22) . Observational studies among noninstitutionalized persons have shown that vaccination of elderly persons is associated with reductions of 30% to 57% in hospitalizations for pneumonia and influenza (6, 7, 13, (23) (24) (25) . Vaccination has also been associated with reductions in deaths from all causes of 27% to 75% (13, 24, 26) . Among elderly nursing home residents, vaccination is associated with a 50% reduction in hospitalizations and a 68% reduction in deaths during influenza seasons (27) .
Among unvaccinated persons, rates of hospitalization due to pneumonia and influenza during the influenza seasons in our study were approximately twice those seen during the interim, noninfluenza periods. Similar excess hospitalization rates have been seen by other investigators during influenza A epidemic years (5, 28, 29) , and smaller increases have been seen during influenza B years (28) . This increase over the rates noted during interim (noninfluenza) periods has been used by others as a measure of the impact of influenza (28, 30) . According to this definition, about half of the hospitalizations due to pneumonia and influenza during the influenza seasons in our study were actually due to influenza. These findings highlight the substantial effect of influenza and its complications on high-risk populations.
The strengths of our study include the use of a narrowly defined cohort of elderly patients in a single managed care health plan (31) . We also had large numbers of persons in both study groups, and we had high event rates, which provided us with adequate power to detect differences between the groups. To adjust for covariates and potential confounders, we did multivariate analyses adjusting for patients' baseline demographic and health characteristics. Nevertheless, our study has several important limitations that are common to observational studies. At baseline, unvaccinated persons differed from vaccinated persons for important characteristics, and our models may not have adequately adjusted for the important differences between the groups (32). Furthermore, our databases did not include information on other variables, such as lifestyle behaviors (including smoking); functional status; and socioeconomic status, which may be associated with both the decision to receive vaccine and the types of outcomes included in this study. We did, however, test the adequacy of the multivariate models by comparing the hospitalization rates of the study groups for two control outcomes: rates of hospitalization for pneumonia during the interim periods and rates of hospitalization for noncardiopulmonary causes during the influenza seasons. For both of these control outcomes, only slight differences were seen between vaccinated and unvaccinated persons, although the CIs, especially for hospitalizations for influenza and pneumonia, were sufficiently wide to prevent us from ruling out clinically important differences during the control periods.
Misclassification of vaccination status may also have occurred, primarily because of failure to capture vaccination status in the administrative databases. If such misclassification were nondifferential, it would have biased the study toward negative findings. However, if it were differential (that is, if it occurred at a different rate among persons with and persons without an outcome event), then the study findings may have been biased in either direction (33) . Two extreme cases would occur if vaccination status was misclassified only among unvaccinated persons who did or did not experience an outcome. If it occurred in those who did experience an outcome, our study findings would overestimate the benefits of vaccination, whereas if it occurred in those who did not experience an outcome, our findings would underestimate the benefits of vaccination. Approximately 95% of the elderly members of this managed care organization, however, reported receiving their influenza vaccinations at one of the organization's clinics (34) . Furthermore, the Group Health databases have been shown to be highly accurate in capturing influenza vaccination status, with 93% agreement between medical records and the computerized databases (Nichol KL. Personal communication). Therefore, we believe that any effect of misclassification would probably have been modest.
Finally, despite the large number of persons included in our study, the CIs around the adjusted risk ratios for differences in hospitalizations for pneumonia and influenza in particular are large. This reflects a smaller number of outcome events or larger variance, or both, than for some of the other outcomes. The point estimates for these outcomes should therefore be interpreted cautiously because they are imprecise.
To conclude, more than 3 million elderly persons in the United States have chronic lung disease and are at especially high risk for complications of influenza. We have shown that vaccination in this very-high-risk group is associated with substantial health benefits. Health care providers should take advantage of every opportunity to immunize these high-risk persons.
